Johnson & Johnson

In J&J’s 44,000-person global trial, the vaccine was found to be 66 per cent effective at preventing moderate-to-severe…

The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial

India, with several vaccine manufacturing facilities, is fast emerging as a key supplier of shots to the world

Biological E has said it can produce 600 million doses for J&J and more than one billion doses a year of its own vaccine,…

This will take the total amount of doses South Africa had been promised to more than 30 million

It aims to deliver 1.3 billion doses of approved vaccines next year to 92 eligible low- and middle-income economies

Vaccine developers are selecting manufacturers that are closer to their homes, which could be due to storage or manufacturing…

Depending on safety and other factors, the company plans to test in even younger children afterwards

The participant's illness is being reviewed and evaluated by an independent data and safety monitoring board, as well as the…

They assured that they will work towards developing innovations to fight the COVID-19 pandemic, ensuring their timely availability…